secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kiniksa Pharmaceuticals International, plc (KNSA)
CIK:        0001730430
Form:       8-K
Filed at:   2022-02-22T23:59:59+00:00
Accession:  0001104659-22-025377
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiniksa and Huadong Medicine $22M upfront Asia Pacific deal; ARCALYST FY2022 rev guidance $115-130M
--------------------------------------------------------------------------------

- Upfront $22M from Huadong; up to $640M milestones + low-teens to low-twenties royalties on net sales for ARCALYST and mavrilimumab in Asia Pacific (ex-Japan).
- ARCALYST net revenue $18.7M Q4 2021, $38.5M FY2021; collaboration achieved profitability in Q4.
- FY2022 ARCALYST net revenue guidance $115-130M; cash $182.2M, no debt, funded into 2024.
- No Phase 3 for mavrilimumab in giant cell arteritis; vixarelimab Phase 2b data in prurigo nodularis expected H2 2022.
- Net loss $36.3M Q4 2021 vs $53.7M Q4 2020; full-year net loss $157.9M vs $161.4M in 2020.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730430/000110465922025377/0001104659-22-025377-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730430/000110465922025377/tm227059d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-025377

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer